Elevated danger of Parkinson’s illness amongst folks with kind 2 diabetes seems to be diminished by some medicines used to deal with their diabetes, finds a brand new examine led by UCL researchers.
The researchers are testing one of many medicine, known as exenatide, as a possible Parkinson’s therapy in an upcoming medical trial, and the brand new findings, revealed in Mind, lend assist to repurposing diabetes medicines for folks with Parkinson’s.
The analysis group, funded by The Treatment Parkinson’s Belief, examined affected person information from 100,288 folks with kind 2 diabetes, from The Well being Enchancment Community database.
The findings confirmed that individuals with kind 2 diabetes face an elevated danger of Parkinson’s, when in comparison with one other cohort of individuals with out diabetes, however generally pharmaceuticals, GLP-1 agonists and DPP4 inhibitors, appeared to reverse that relationship.
The researchers discovered that individuals who had been taking two explicit courses of diabetes remedies—GLP-1 agonists (reminiscent of exenatide) and DPP4 inhibitors—had been much less prone to be identified with Parkinson’s illness a number of years later (common comply with up time of three.3 years), in comparison with individuals who had been taking different diabetes medications. These taking GLP-1 agonists had been 60% much less prone to develop Parkinson’s in comparison with folks taking different diabetes medicine.
This examine offers additional verification for a part 3 medical trial of exenatide for folks with Parkinson’s, led by Professor Tom Foltynie (UCL Queen Sq. Institute of Neurology), co-lead creator of this examine. The upcoming trial is at the moment recruiting 200 folks with Parkinson’s throughout the UK. An earlier examine discovered that individuals with Parkinson’s who injected themselves every week with exenatide for one 12 months carried out higher in motion exams than those that injected a placebo.
Professor Foltynie stated: “Our examine has strengthened proof that there’s a hyperlink between kind 2 diabetes and Parkinson’s illness, though it stays clear that most individuals with diabetes won’t go on to develop Parkinson’s.
“We have now added to proof that exenatide might assist to forestall or deal with Parkinson’s illness, hopefully by affecting the course of the illness and never merely lowering signs, however we have to progress with our medical trial earlier than making any suggestions.”
Co-lead creator Professor Li Wei (UCL College of Pharmacy) stated: “It might be useful for medical doctors to think about different risk factors for Parkinson’s illness when prescribing medicines for kind 2 diabetes, however additional analysis will likely be wanted to verify medical implications.”
Ruth Brauer et al. Diabetes medicines and danger of Parkinson’s illness: a cohort examine of sufferers with diabetes, Mind (2020). DOI: 10.1093/brain/awaa262
University College London
Frequent diabetes medicine might forestall Parkinson’s (2020, October 27)
retrieved 28 March 2021
This doc is topic to copyright. Other than any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for data functions solely.